[交流] FDA批准的一种美容药 已有1人参与

The prostaglandin analogue bimatoprost (Latisse&reg, which has been marketed by Allergan since 2001 for the treatment of glaucoma, was launched last year for an entirely new indication: the treatment of hypotrichosis of eyelashes. Patients with this medical aesthetic condition have inadequate or not enough eyelashes. The new indication was discovered serendipitously, upon the observation that patients using bimatoprost to treat open-angle glaucoma experienced eyelash growth as a side effect. In subsequent clinical studies, Allergan demonstrated that the once-daily application of bimatoprost led to improved eyelash length, thickness and darkness, together with a favorable safety profile.

回复此楼